News &amp; Updates

The oral, dual peroxisome proliferator-activated receptor-α/δ agonist elafibranor improves biomarkers of cholestasis and quells itching in patients with primary biliary cholangitis, while having an acceptable safety profile, as shown in the phase III ELATIVE study.

Endoscopic ultrasound-guided CPN effective for abdominal pain in pancreatic cancer

Endoscopic ultrasound-guided celiac plexus neurolysis added to medical management (EUS-CPN+MM) provides beneficial effects for abdominal pain in patients with unresectable pancreatic cancer at 4 and 12 weeks, reports a recent study.

29 Nov 2023

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

Patients with functional dyspepsia (FD) may benefit from transcutaneous neuromodulation (TN) treatment, which can significantly improve symptoms and quality of life, according to a study.

29 Nov 2023

Continuous vs intermittent feeding: Which is better for critically ill patients?

Continuous feeding appears to be more effective than intermittent feeding in reducing the rate of mortality in critically ill patients in the intensive care unit (ICU), reveals a study.

Simplified, tailored treatment for asthma improves patient outcomes

Asthma is a highly prevalent disease that can affect anybody regardless of age, race, and location. The overall burden of asthma remains severe. Despite the range of available therapies and well-established guidelines, there remains a significant unmet need in the management of asthma. [BMC Public Health 2012;12:860; Respir Res 2023;24:169; Eur Respir J 2014;43:343-373]

29 Nov 2023

Pre-eclampsia ups venous thromboembolism risk during pregnancy

Women with a history of pre-eclampsia are at increased risk of venous thromboembolism during pregnancy, according to a study.

COVID-19 infection ups CV risk in people living with HIV

People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.

29 Nov 2023

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

28 Nov 2023 by

Viral suppression is maintained through 48 weeks in adults with HIV-1 harbouring drug resistance mutations, who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination pill from a boosted protease inhibitor (bPI) therapy, according to recent data from the phase IV open-label PIBIK trial.

Some signal of benefit found for liberal transfusion strategy for anaemic heart attack patients

28 Nov 2023 by

Adopting a liberal blood transfusion strategy in patients with acute myocardial infarction (AMI) and anaemia does not appear to do much in terms of reducing the risk of AMI recurrence or death compared with a restrictive transfusion strategy, although there appears to be a hint of benefit, as shown in the results of the phase III MINT trial.

HRV/EV infections affect the respiratory system, yield low mortality rates

The respiratory system is the main target of human rhinovirus/enterovirus (HRV/EV) infections, which show a clinical course with low mortality rates, reveals a study.